The Country Doctor' Who Upended Our Understanding of Dementia
Dr. Francisco Lopera's pioneering work in Alzheimer's research was characterized by his deep commitment to understanding familial and genetic links to dementia.
How long COVID could lift the fog on neurocognitive disorders
Long COVID's neurocognitive symptoms significantly impact daily life, comparable to age-related cognitive impairments.
Current understanding and research on cognitive impairment related to COVID-19 require urgent attention.
The Country Doctor' Who Upended Our Understanding of Dementia
Dr. Francisco Lopera's pioneering work in Alzheimer's research was characterized by his deep commitment to understanding familial and genetic links to dementia.
How long COVID could lift the fog on neurocognitive disorders
Long COVID's neurocognitive symptoms significantly impact daily life, comparable to age-related cognitive impairments.
Current understanding and research on cognitive impairment related to COVID-19 require urgent attention.
The latest Alzheimer's drugs have limited effectiveness and potential serious side effects, prompting researchers to explore new options.
Mesulam Center Celebrates 30th Annual Alzheimer Day: Recognizing Scientific Achievement and Bringing Awareness to Early-Onset Dementia
The Mesulam Center for Cognitive Neurology and Alzheimer's Disease is actively involved in researching Alzheimer's, including recent pharmaceutical breakthroughs like Lecanamab and Donanemab.
Where the future of Alzheimer's drugs is heading
The latest Alzheimer's drugs have limited effectiveness and potential serious side effects, prompting researchers to explore new options.
Mesulam Center Celebrates 30th Annual Alzheimer Day: Recognizing Scientific Achievement and Bringing Awareness to Early-Onset Dementia
The Mesulam Center for Cognitive Neurology and Alzheimer's Disease is actively involved in researching Alzheimer's, including recent pharmaceutical breakthroughs like Lecanamab and Donanemab.
Alzheimer's scientist indicted for allegedly falsifying data in $16M scheme
An Alzheimer's researcher allegedly falsified data to secure $16 million in research funding for an Alzheimer's drug, raising doubts about the integrity of the research.
The investigation revealed long-standing and egregious misconduct in data management by the researcher, leading to questions about the authenticity of the work.